日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map

Brolucizumab治疗新生血管性年龄相关性黄斑变性的安全性结果:来自IRIS注册研究和Komodo医疗保健地图的结果

Khanani, Arshad M; Zarbin, Marco A; Barakat, Mark R; Albini, Thomas A; Kaiser, Peter K; B, Guruprasad; Agashivala, Neetu; Yu, Justin S; Wykoff, Charles C; MacCumber, Mathew W

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis

Brolucizumab 与 aflibercept 和 ranibizumab 治疗新生血管性年龄相关性黄斑变性:一项成本效益分析

Yu, Justin S; Carlton, Rashad; Agashivala, Neetu; Hassan, Tarek; Wykoff, Charles C

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

在复发型多发性硬化症患者中,改用芬戈莫德与继续使用醋酸格拉替雷或β干扰素相比,对患者和医生报告结局的影响:EPOC试验的事后分析

Calkwood, Jonathan; Cree, Bruce; Crayton, Heidi; Kantor, Daniel; Steingo, Brian; Barbato, Luigi; Hashmonay, Ron; Agashivala, Neetu; McCague, Kevin; Tenenbaum, Nadia; Edwards, Keith

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry

NARCOMS注册研究中患者对疾病修饰疗法转换的看法

Salter, Amber R; Marrie, Ruth Ann; Agashivala, Neetu; Belletti, Daniel A; Kim, Edward; Cutter, Gary R; Cofield, Stacey S; Tyry, Tuula

Treatment selection and experience in multiple sclerosis: survey of neurologists

多发性硬化症的治疗选择和经验:神经科医生调查

Hanson, Kristin A; Agashivala, Neetu; Wyrwich, Kathleen W; Raimundo, Karina; Kim, Edward; Brandes, David W

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

多发性硬化症患者对芬戈莫德和其他疾病修饰疗法的依从性:一项回顾性队列研究

Agashivala, Neetu; Wu, Ning; Abouzaid, Safiya; Wu, You; Kim, Edward; Boulanger, Luke; Brandes, David W